WEBULL
WebtradeDownload

Sonic Healthcare (ASX:SHL) Shares Face Margin Recovery Questions Despite Higher Profit

Simply Wall St · 2d ago

Sonic Healthcare walked into this result with the stock roughly flat over the past month and still recovering over the quarter. Yet the fresh numbers show why income focused holders are likely paying attention. Full year revenue reached about A$10.9b and net profit margin edged up to 5.6%, a modest improvement that matters in low margin diagnostics. With the shares closing at A$21.08 on 21 August and the trailing dividend yield at 5.12%, the market reaction looks more cautious than the headline earnings suggest.

Is Sonic Healthcare a clear bargain at a 17.1x P/E and a share price well below the A$61.94 DCF estimate, or is the longer earnings track record flashing a warning sign? Compare how this pricing stacks up against cash flows and sector peers on our valuation analysis for Sonic Healthcare

FY 2026 Earnings Summary

  • Revenue (FY 2026 vs FY 2025 PCP): A$10,867.37m vs. A$9,645.45m (higher year on year)
  • Net Income (Excl. Extra Items, FY 2026 vs FY 2025 PCP): A$608.29m vs. A$513.60m (higher year on year)
  • Basic EPS (Earnings Per Share, FY 2026 vs FY 2025 PCP): A$1.23 vs. A$1.07 (higher year on year)
  • Net Profit Margin (FY 2026 vs prior year): 5.6% vs. 5.3% (slight margin improvement)

Prefer clear, visual charts instead of another dense page of Sonic Healthcare numbers? See the full picture of the company’s valuation in an easy-to-scan format through our company report for Sonic Healthcare.

ASX:SHL Trailing 12-Month Earnings & Revenue History as at Aug 2026
ASX:SHL Trailing 12-Month Earnings & Revenue History as at Aug 2026

Sonic Healthcare’s Margin Repair Story Shows Early Wins

Bulls argue Sonic Healthcare can rebuild profitability through efficiency gains, higher value testing and better use of its fixed lab network. The latest result gives that view some tangible support. Revenue reached about A$10.9b while net income excluding extra items was A$608.29m, and net profit margin lifted to 5.6% from 5.3%. That margin shift is small in percentage terms but important in a business where wages and reimbursement have been squeezing earnings.

The earlier narrative highlighted lab integration, revenue cycle upgrades and labour cost control as key levers. The combination of higher revenue, higher net income and improved basic EPS at A$1.23 versus A$1.07 indicates some of those levers are now flowing through the income statement. It does not prove the full margin recovery story yet, but it does show Sonic Healthcare is hitting early milestones that bulls had been waiting to see in the reported numbers.

Access where the surface looks calm but the models start to diverge on Sonic Healthcare’s next few years by checking the revenue, earnings and free cash flow analyst estimates for Sonic Healthcare.

Sonic Healthcare Bears Still Waiting On Key Proof Points

The cautious narrative around Sonic Healthcare argues that integration hurdles, capital heavy radiology spend and reimbursement pressure will keep margins under strain even as revenue grows. The latest A$10.9b revenue and 5.6% net margin do not fully disprove that view. Profitability has improved only modestly compared with the prior year, despite earlier concerns about wage and funding pressure already being well known. That suggests some cost overhang remains rather than a clean reset.

Bears also warned that higher value tests and contract wins might dilute margins at first. The numbers are consistent with that pattern. Net income and EPS moved higher, yet there is no evidence here of a step change in margin, or of genetics and complex testing clearly lifting the overall mix. With the share price roughly flat over 7 days and only modestly higher over 30 days, the market reaction points to progress, but not a missed bear thesis.

With Sonic Healthcare still balancing a multi year earnings decline against only modest margin repair, the real question is whether cash, debt and interest cover comfortably support that 5.12% yield and any further turnaround spend. Check the full solvency, liquidity and leverage breakdown in our financial health analysis of Sonic Healthcare stock.

Shape Your Next Investment Move

If Sonic Healthcare’s 5.6% margin and 5.12% yield have put it on your radar, register for free with Simply Wall St and add it to a Watchlist to track the share price against fair value and watch for an entry point that fits your plan. Once you are invested, use the Portfolio Command Center to cut through noise and focus on the updates that really matter for your holdings. For longer term decisions, tap into crowd wisdom and see what other investors are thinking through the Community. By spotting hidden catalysts and risks early, you give yourself a better chance to stay ahead of the market.

Seeking Alternatives Beyond Sonic Healthcare?

Fresh stock ideas can move from quiet to breakout before most investors notice. Use these curated lists while the data is fresh and under the radar for now. Act now.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.